The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).
 
Andrea S. Fung
No Relationships to Disclose
 
Vincent C. Tam
Honoraria - Apobiologix; Celgene
Travel, Accommodations, Expenses - Amgen
 
Daniel E. Meyers
No Relationships to Disclose
 
Hao-Wen Sim
No Relationships to Disclose
 
Jennifer J. Knox
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Merck
Research Funding - AstraZeneca
 
Valeriya O. Zaborska
No Relationships to Disclose
 
Janine Marie Davies
Honoraria - Bayer
Consulting or Advisory Role - Amgen; Ipsen; Shire
Speakers' Bureau - Roche Canada
Travel, Accommodations, Expenses - Bayer
 
Yoo-Joung Ko
Honoraria - Celgene; Lilly
Consulting or Advisory Role - Celgene; Lilly
Research Funding - Celgene
Travel, Accommodations, Expenses - Celgene
 
Eugene Batuyong
No Relationships to Disclose
 
Winson Y. Cheung
No Relationships to Disclose
 
Haider Samawi
No Relationships to Disclose
 
Richard M. Lee-Ying
Consulting or Advisory Role - Celgene
Speakers' Bureau - Celgene